TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration

PURPOSE: To describe the design and rationale of the phase 3 TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT03823300) trials that aimed to assess efficacy, safety, and durability of faricimab, the first bispecific antibody for intraocular use, whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanani, Arshad M., Guymer, Robyn H., Basu, Karen, Boston, Heather, Heier, Jeffrey S., Korobelnik, Jean-François, Kotecha, Aachal, Lin, Hugh, Silverman, David, Swaminathan, Balakumar, Willis, Jeffrey R., Yoon, Young Hee, Quezada-Ruiz, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559073/
https://www.ncbi.nlm.nih.gov/pubmed/36246941
http://dx.doi.org/10.1016/j.xops.2021.100076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559073/
https://www.ncbi.nlm.nih.gov/pubmed/36246941
http://dx.doi.org/10.1016/j.xops.2021.100076

Ejemplares similares